SEC Filing Intelligence
Biotech BD & Licensing Events
Classified 8-K events from SEC EDGAR: licensing agreements, strategic alternatives, M&A signals, and financing activity. Tagged by deal type and linked to company identifiers. Updated 3× daily from primary filings.
Request dataset →Live Sample
What the data looks like
Live data from our pipeline.
Context Therapeutics Inc. amended its license agreement with BioAtla, Inc. for exclusive rights to certain antibody assets, including CT-202. The amendment makes the licenses irrevocable, royalty-free, fully paid-up, and non-terminable, eliminating future milestone payments and royalties to BioAtla. Context Therapeutics will pay BioAtla $4.5 million within five business days and an additional $2.0 million by August 1, 2026 for these modified terms.
Atara Biotherapeutics, Inc. announced a regulatory update regarding its drug EBVALLO™. The company held a Type A meeting with the FDA to discuss the Complete Response Letter (CRL) issued on January 9, 2026, for the EBVALLO™ Biologics License Application.
Genprex announced positive preclinical data for its diabetes gene therapy, GPX-002 (Pdx1/MafA gene therapy), presented at the ASGCT Annual Meeting. The data demonstrated that the therapy reversed hyperglycemia and improved beta-cell function and maturation in Type 2 diabetic mouse models. This preclinical success is considered a pivotal step towards a potentially transformative treatment for T2D, aiming for long-term glycemic control by directly addressing beta-cell dysfunction.
Silence Therapeutics plc entered into a new Open Market Sale Agreement with Jefferies LLC on May 18, 2026, establishing an at-the-market offering program for its American Depositary Shares. This agreement replaces a prior one with Jefferies and does not obligate the company to sell any ADSs. Additionally, the company updated its disclosures, now believing it was not classified as a passive foreign investment company (PFIC) for the taxable year ended December 31, 2025, following further tax analysis.
Allogene Therapeutics terminated its Exclusive License Agreement with Overland Therapeutics, effective May 12, 2026. This agreement, originally signed in December 2020, granted Overland exclusive rights to develop and commercialize allogeneic CAR T cell therapies targeting BCMA, CD70, FLT3, and DLL3 in specific Asian territories. No termination payments were exchanged, and Allogene reduced its equity stake in Overland to approximately 3%.
Live data from our pipeline. The structured export includes all fields listed below.
Use Cases
Who Uses This Data
Structured for direct analysis. No data cleaning, no manual joins required.
Healthcare Investment Banking
- ● Track licensing deal flow across therapeutic areas for pitch book and comp research
- ● Monitor strategic alternative announcements as M&A lead indicators
- ● Identify financing events and proceeds amounts for comparable transaction analysis
- ● Export structured deal data to populate precedent transaction databases
Corporate Business Development
- ● Monitor competitor licensing activity in your therapeutic area as it files
- ● Track strategic review announcements as potential partnership or acquisition signals
- ● Stay current on financing events that indicate pipeline funding status
- ● Cross-reference deal signals with clinical trial milestones for full pipeline context
What's Included
Data Fields
Primary Sources
- • SEC EDGAR 8-K filings (primary source)
- • 500+ tracked public biotech companies
- • Auto-classification by deal type and signal category
Fields Include
- • Company name, ticker, and SEC CIK
- • Filing date and 8-K accession number
- • Signal type (Licensing, Strategic Review, M&A, Financing, FDA Action, Clinical Data)
- • Deal excerpt auto-extracted from filing text
- • Counterparty name (where detectable)
- • Proceeds amount (financing events)
- • Link to original SEC EDGAR document
- • Linked trial count and phase distribution per company
Get the Data
Got it.
We'll follow up shortly.